What I'm saying is that if you look at the paid plasma system and the unpaid blood system, the donors coming in may indeed have different seroprevalence rates for hepatitis and HIV.
What we cannot say categorically is that it's simply because you're paying them. They collect in different markets. They have a slightly different set of questions. They have slightly different processes. Is it the act alone of paying that is causing that raw seroprevalence data to be slightly different? We don't know that for sure.
The only abundantly clear evidence, which I keep coming back to, is the finished product. What you're asking me is whether the act of paying, in and of itself, raises the risk of HIV in the donors coming in. What you have to recognize is that the way the paid plasma industry operates—where it sets up clinics, how it recruits donors—is markedly different from what the not-for-profit unpaid blood system does, so you're not comparing like for like. That's the important distinction I'm trying to make.